Recklinghausen’s neurofibromatosis associated with the development of malignant schwannoma
https://doi.org/10.51523/2708-6011.2026-23-1-15
Abstract
The article presents a clinical case of a rare disease neurofibromatosis (NF). Typical clinical symptoms, diagnostic and therapeutic tactics are demonstrated. The problems of cancer alertness and malignancy are touched on. Patients with NF1 have a high risk of developing neoplasms, including a high risk of malignancy, which significantly reduces the life expectancy of these people.
About the Authors
N. M. Vishareva
Gomel State Medical University
Belarus
Belarus
Nadezda M. Vishareva, Senior Lecturer at the Department of Propaedeutics of Internal Diseases
Gomel
I. A. Kulikova
Gomel State Medical University
Belarus
Belarus
Iryna A. Kulikova, Assistant at the Department of Propaedeutics of Internal Diseases
Gomel
References
1. Choi J, An S, Lim SY. Current concepts of neurofibromatosis type 1: pathophysiology and treatment. Arch Craniofac Surg. 2022 Feb;23(1):6-16. DOI: https://doi.org/10.7181/acfs.2022.00633
2. Schneider NA, Gorelov AI. Neurofibromatosis of the first type (Recklinghausen disease). Siberian Medical Review; 2007;(3). [access date: 25.03.2024]. Available from: https://cyberleninka.ru/article/n/neyrofibromatoz-pervogo-tipa-bolezn-reklinghauzena/viewer
3. Tamura R. Current Understanding of Neurofibromatosis Type 1, 2, and Schwannomatosis. Int J Mol Sci. 2021 May 29;22(11):5850. DOI: https://doi.org/10.3390/ijms22115850
4. Seed S. Neurofibromatosis [access date: 25.03.2025]. Available from https://www.webmd.com/pain-management/neurofibromatosis
5. Ghalayani P, Saberi Z, Sardari F. Neurofibromatosis type I (von Recklinghausen’s disease): A family case report and literature review. Dent Res J (Isfahan). 2012 Jul;9(4):483-488.
6. Ufimtseva MA, Bochkarev YuM, Galperin AM, Golovyrina IL, Gurkovskaya EP. Cutaneous manifestations of the disease reklingauzena. Modern problems of science and education. 2016;(6). [access date: 25.03.2025] Available from: https://science-education.ru/ru/article/view?id=25818
7. Hua C, Zehou O, Ducassou S, Minard-Colin V, Hamel-Teillac, D, Wolkenstein P, Valeyrie-Allanore L. Sirolimus Improves Pain in NF1 Patients with Severe Plexiform Neurofibromas. Pediatrics. 2014 Jun;133(6):e1792-e1797. DOI: https://doi.org/10.1542/peds.2013-1224
8. Slopis JM, Arevalo O, Bell CS, Hebert AA, Northrup H, Riascos RF, et al. Treatment of Disfiguring Cutaneous Lesions in Neurofibromatosis-1 with Everolimus: A Phase II, Open-Label, Single-Arm Trial. Drugs R D. 2018 Dec;18(4):295-302. DOI: https://doi.org/10.1007/s40268-018-0248-6
9. Casey D, Demko S, Sinha A, Mishra-Kalyani PS, Shen YL, Khasar S, et al. FDA Approval Summary: Selumetinib for Plexiform Neurofibroma. Clin Cancer Res. 2021 Aug 1;27(15):4142-4146. DOI: https://doi.org/10.1158/1078-0432.CCR-20-5032
10. Gross A, Wolters P, Baldwin A, Dombi E, Fisher Mj, Weiss B, et al. Widemann Bc. Nfm-07. Sprint: Phase Ii Study of The Mek 1/2 Inhibitor Selumetinib (Azd6244, Arry-142886) In Children with Neurofibromatosis Type 1 (Nf1) And Inoperable Plexiform Neurofibromas (Pn). Neuro Oncol. 2018 Jun;20(Suppl 2):143-144. DOI: https://doi.org/10.1093/Neuonc/Noy059.515
11. Bahir H Chamseddin, Lu Q Le. Management of cutaneous neurofibroma: current therapy and future directions. Neuro-Oncology Advances/ 2020;2(Supplement_1):i107–i116. DOI: https://doi.org/10.1093/noajnl/vdz034
12. Wozniak B, Bove T, Zawada T, Calik J. Treatment of Cutaneous Neurofibromas in Patients with Neurofibromatosis Type 1. Case Rep Dermatol. 2023 Oct 20;15(1):194-201. DOI: https://doi.org/10.1159/000534270
13. Chamseddin BH, Hernandez L, Solorzano D, Vega J, Le LQ. Robust surgical approach for cutaneous neurofibroma in neurofibromatosis type 1. JCI Insight. 2019 Apr 30;5(11): e128881. DOI: https://doi.org/10.1172/jci.insight.128881
14. Poplausky D, Young JN, Tai H, Rivera-Oyola R, Gulati N, Brown RM. Dermatologic Manifestations of Neurofibromatosis Type 1 and Emerging Treatments. Cancers (Basel). 2023 May 16;15(10):2770. DOI: https://doi.org/10.3390/cancers15102770
Review
For citations:
Vishareva N.M., Kulikova I.A. Recklinghausen’s neurofibromatosis associated with the development of malignant schwannoma. Health and Ecology Issues. 2026;23(1):128-133. (In Russ.) https://doi.org/10.51523/2708-6011.2026-23-1-15
Views:
103
JATS XML
Email this article 